Loading...
Market
Will Myricx Pharma's NMTi-ADC therapeutics show positive results in preclinical studies by Q1 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcements from Myricx Pharma or scientific publications
Story
London-Based Myricx Pharma Raises £90 Million in 2024 Series A for Cancer Drug Development
Jul 8, 2024, 05:42 AM
British biotech spinout Myricx Pharma, based in London, has successfully raised £90 million ($115 million) in a series A financing round in 2024. The funding, which is one of the largest in recent years in the UK, includes contributions from investors such as the controlling shareholder of Ozempic maker Novo Nordisk and SofinnovaVC. The capital will be utilized to advance Myricx's novel N-myristoyltransferase (NMT) inhibitor antibody-drug conjugates (NMTi-ADC) therapeutics into clinical development. CEO Robin Carr highlighted the company's innovative NMT payload approach to ADCs. This significant investment underscores the growing interest and commitment to cancer treatment advancements.
View original story
Similar markets
Yes • 50%
No • 50%
Complete Response • 25%
Partial Response • 25%
Stable Disease • 25%
Progressive Disease • 25%
Yes • 50%
No • 50%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worse outcomes • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Highly Effective • 25%
Moderately Effective • 25%
Minimally Effective • 25%
Ineffective • 25%
Trial halted • 25%
Limited efficacy • 25%
Moderate efficacy • 25%
High efficacy • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results published • 25%
